Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05782361 |
| Title | POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC (POTENT) |
| Acronym | POTENT |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Institute of Cancer Research, United Kingdom |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | GBR |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| DDU, Royal Marsden Hospital NHS Foundation Trust | RECRUITING | Sutton | Surrey | SM2 5PT | United Kingdom | Details |
| University College London Hospitals NHS Foundation Trust | NOT_YET_RECRUITING | London | NW1 2BU | United Kingdom | Details | |
| Lung Unit, Royal Marsden Hospital NHS Foundation Trust | NOT_YET_RECRUITING | London | SW3 6JJ | United Kingdom | Details | |
| The Christie NHS Foundation Trust | RECRUITING | Manchester | M20 4BX | United Kingdom | Details |